Drug Type Small molecule drug |
Synonyms Radezolid (USAN/INN), Radezolid Hydrochloride, AND RX-01_667 + [8] |
Target |
Action modulators, inhibitors |
Mechanism 23S rRNA modulators(23S Ribosomal RNA modulators), 50S subunit inhibitors(50S ribosomal subunit inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23FN6O3 |
InChIKeyBTTNOGHPGJANSW-IBGZPJMESA-N |
CAS Registry869884-78-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Abscess | Phase 2 | United States | 01 Dec 2007 | |
Complicated skin and skin structure infection | Phase 2 | United States | 01 Dec 2007 | |
Staphylococcal Skin Infections | Phase 2 | United States | 01 Dec 2007 | |
Streptococcal Infections | Phase 2 | United States | 01 Dec 2007 | |
Community Acquired Pneumonia | Phase 2 | United States | 01 Oct 2007 | |
Community Acquired Pneumonia | Phase 2 | Canada | 01 Oct 2007 | |
Community Acquired Pneumonia | Phase 2 | Russia | 01 Oct 2007 | |
Mycobacterium Abscessus Infection | Preclinical | South Korea | 26 Apr 2018 | |
MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | United States | 05 Jul 2008 | |
Vancomycin-resistant enterococcal infection | Preclinical | United States | 05 Jul 2008 |
Phase 2 | 158 | (Radezolid 300 mg PO Daily (QD)) | xnfmffkfng = ovobrfkpvt pubahzwjrv (yukwjwfyid, vhaacdrocl - fzxiqcwzap) View more | - | 04 Feb 2010 | ||
(Radezolid 450 mg PO Daily (QD)) | xnfmffkfng = bugtwedwfe pubahzwjrv (yukwjwfyid, bdacycplcu - hqzlxriihn) View more | ||||||
Phase 2 | 150 | (Radezolid QD) | elfnjjogke = vueewbnnlq ttpvnalyrc (mblgfadecs, reijxnuwkl - xfvjrovteb) View more | - | 26 Jun 2009 | ||
(Radezolid BID) | elfnjjogke = qlebfdaavo ttpvnalyrc (mblgfadecs, jrhpyzbsbz - erxwjlphyz) View more |